FDA — authorised 29 March 2013
- Application: NDA204042
- Marketing authorisation holder: JANSSEN PHARMS
- Local brand name: INVOKANA
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Canagliflozin - SGLT2i in United States
FDA authorised Canagliflozin - SGLT2i on 29 March 2013
Marketing authorisation
Canagliflozin - SGLT2i in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Diabetes approved in United States
Frequently asked questions
Is Canagliflozin - SGLT2i approved in United States?
Yes. FDA authorised it on 29 March 2013.
Who is the marketing authorisation holder for Canagliflozin - SGLT2i in United States?
JANSSEN PHARMS holds the US marketing authorisation.